Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

Maurie Markman, Robert Rothman, Thomas B. Hakes et al. · Journal of Clinical Oncology · 1991 · 854 citations

Medicine, Gynecology, Oncology +13

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 619 citations

Medicine, Gynecology, Oncology +17

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Gordon Rustin, Maria EL van der Burg, Clare Griffin et al. · The Lancet · 2010 · 594 citations · Full text

Medicine, Gynecology, Oncology +15

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

Martin Gore, I Fryatt, E. Wiltshaw et al. · Gynecologic Oncology · 1990 · 392 citations

Medicine, Oncology, Pharmacology +14